RIL
BCAX

Rothschild Investment LLC’s Bicara Therapeutics BCAX Stock Holding History

Rothschild Investment LLC’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$891 Hold
30
– – ﹤0.01% 3087
2026
Q1 		$597 Buy
+30
New +$516 ﹤0.01% 3060
2025
Q2 		– Sell
-20
Closed -$261 – 3211
2025
Q1 		$261 Buy
+20
New +$266 ﹤0.01% 2790

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rothschild Investment LLC's BCAX Position: Q2 2026 in Review

Rothschild Investment LLC held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 30 shares worth $891. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

Rothschild Investment LLC first reported a position in BCAX in Q1 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Rothschild Investment LLC held 30 shares of Bicara Therapeutics worth $891 as of Q2 2026.
  • Rothschild Investment LLC left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3087 holding.
  • Rothschild Investment LLC first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.